Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR2 | P41597 | 5/20 | 0.46 |
| ▸ | KIF11 | P52732 | 1/20 | 0.45 |
| ▸ | PAK1 | Q13153 | 1/20 | 0.45 |
| ▸ | RORC | P51449 | 4/20 | 0.44 |
| ▸ | GPR6 | P46095 | 5/20 | 0.42 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.41 |
| ▸ | BTK | Q06187 | 1/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.41 |
| ▸ | PHGDH | O43175 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2271430 | 0.90 | CXCR3 (0.48) | GPR6 | |
| SCHEMBL2273727 | 0.88 | KIF11 (0.44) | CCR2KIF11PAK1KCNH2PHGDH | |
| SCHEMBL2267997 | 0.88 | KIF11 (0.44) | CCR2KIF11PAK1KCNH2PHGDH | |
| SCHEMBL2275026 | 0.88 | KIF11 (0.44) | CCR2KIF11PAK1KCNH2PHGDH | |
| SCHEMBL2271014 | 0.84 | CXCR3 (0.55) | GPR6BTK | |
| SCHEMBL2275479 | 0.83 | PAK1 (0.46) | CCR2PAK1KCNH2 | |
| SCHEMBL2271376 | 0.83 | PAK1 (0.46) | CCR2PAK1KCNH2 | |
| SCHEMBL2270608 | 0.81 | CXCR3 (0.57) | CCR2KIF11BTKKCNH2 | |
| SCHEMBL2268315 | 0.81 | CXCR3 (0.57) | CCR2KIF11BTKKCNH2 | |
| SCHEMBL2222953 | 0.81 | RORC (0.43) | PAK1RORCGPR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130029971-A1 | CXCR3 RECEPTOR ANTAGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-01-31 | — | — | US | claimed |
| WO-2011084985-A1 | CXCR3 RECEPTOR ANTAGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-07-14 | — | — | WO | claimed |
| US-8952004-B2 | CXCR3 receptor antagonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-02-10 | — | — | US | disclosed |
| US-8952004-B2 | CXCR3 receptor antagonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-02-10 | — | — | US | disclosed |
| US-20130029971-A1 | CXCR3 RECEPTOR ANTAGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-01-31 | — | — | US | disclosed |
| US-20130029971-A1 | CXCR3 RECEPTOR ANTAGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-01-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130029971-A1 | CXCR3 RECEPTOR ANTAGONISTS | CXCR3, CXCR1, CXCR2 | CCR2 13/4885KIF11 4183/4885PAK1 1014/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.